A Korean Patient With Fulminant Autoantibody-Negative Type 1 Diabetes
- Tae S. Jung, MD1,
- Soon I. Chung, MD, PHD12,
- Me A. Kim, MD, PHD23,
- Sun J. Kim, MD, PHD23,
- Myoung H. Park, MD, PHD4,
- Deok R. Kim, PHD5,
- Mi Y. Kang, MD1 and
- Jong R. Hahm, MD, PHD12
- 1Department of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju, Korea
- 2Gyeongsang Institute of Health Science, Jinju, Korea
- 3Department of Laboratory Medicine, College of Medicine, Gyeongsang National University, Jinju, Korea
- 4Department of Laboratory Medicine, Seoul National University, Seoul, Korea
- 5Department of Biochemistry, College of Medicine, Gyeongsang National University, Jinju, Korea
- Address correspondence to Jong R. Hahm, MD, PhD, Gyeongsang National University Hospital, 90, Chilamdong, Jinju, Korea. E-mail: jrhahm{at}gshp.gsnu.ac.kr
Since 11 novel cases of fulminant autoantibody-negative type 1 diabetes were introduced by Imagawa and colleagues (1,2), about 150 additional cases have been reported. The development of typical fulminant autoantibody-negative type 1 diabetes is strictly confined to Japan. Although the pathogenetic mechanism still remains unclear, there is some evidence supporting the immunogenetic predisposition mechanism in the development of this subtype. A fulminant autoantibody-negative type 1 diabetic patient with insulitis and exocrine pancreatitis showed infiltration of a large number of CD8+ T-cell and peripheral GAD-reactive interferon-γ-producing CD4+ T-cell (3). According to previous reports, some HLA haplotypes, DRB1*0405-DQB1*0401, DQA1*0303-DQB1*0401, DQA1*0302-DQB1*0303, and DRB*0901 are closely associated with fulminant autoantibody-negative …
